ArticleFrontiers in microbiology2017
Fingerprint Analysis and Identification of Strains ST309 as a Potential High Risk Clone in a
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Extensively and Pan-Drug Resistant Pseudomonas aeruginosa Strains from Burn Patients in Mexico City are Genetically Related to Isolates Recovered a Decade Earlier in Local Hospitals.Current microbiology · 2026Article
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- Phylogenomic and phenotypic profiling of carbapenem-resistantMicrobial genomics · 2026Article
- Molecular Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Integron architecture and virulence-associated gene profiles in extensively drug-resistant high-riskFrontiers in microbiology · 2026Article
- First nationwide survey onAntimicrobial agents and chemotherapy · 2025Article
- Interplay between T3SS effectors, ExoY activation, and cGMP signaling in Pseudomonas aeruginosa infection.Nature communications · 2025Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Antibiotic Resistance and Virulence Determinants ofMicroorganisms · 2025Article
- ThePathogens (Basel, Switzerland) · 2024Article
- Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2024Article
- Pseudomonas aeruginosa from river water: antimicrobial resistance, virulence and molecular typing.FEMS microbiology ecology · 2024Article
- Outbreak ofAntibiotics (Basel, Switzerland) · 2024Article
- Evolving landscape of carbapenem-resistantJAC-antimicrobial resistance · 2023Article
- Detection of Antibiotic Resistance Genes (Archives of Razi Institute · 2023Article
- Genetic Diversity, Biofilm Formation, and Antibiotic Resistance ofVeterinary sciences · 2022Article
- Diversity in the composition of the accessory genome of Mexican Pseudomonas aeruginosa strains.Genes & genomics · 2022Article
- Genetic Diversity of Multidrug-ResistantFrontiers in microbiology · 2021Article
- Virulence and resistance determinants inJournal of advanced veterinary and animal research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.